David Amsellem
Stock Analyst at Piper Sandler
(4.84)
# 398
Out of 4,456 analysts
903
Total ratings
60.9%
Success rate
14.6%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterated: Buy | $298 | $253.35 | +17.62% | 21 | Jun 23, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $43 | $55.08 | -21.93% | 40 | Jun 22, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $258 | $241.67 | +6.76% | 25 | Jun 17, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $301 | $230.02 | +30.86% | 67 | Jun 16, 2026 | |
| AMGN Amgen | Reiterated: Buy | $427 | $358.33 | +19.16% | 48 | Jun 12, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterated: Buy | $42 | $33.21 | +26.47% | 67 | Jun 10, 2026 | |
| VTRS Viatris | Maintained: Hold | $12 | $16.33 | -26.52% | 24 | Jun 4, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $66 | $46.84 | +40.91% | 69 | Jun 4, 2026 | |
| AMRX Amneal Pharmaceuticals | Maintained: Buy | $17 | $17.23 | -1.33% | 41 | Jun 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 | $57.52 | +30.39% | 17 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $87.32 | +0.78% | 31 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 | $216.03 | +4.15% | 29 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 → $59 | $41.83 | +41.05% | 14 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $11.02 | +63.34% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $4.39 | +82.23% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $25 → $21 | $21.78 | -3.58% | 40 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $48 | $44.95 | +6.79% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $179 → $207 | $168.52 | +22.83% | 42 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $9 → $3.16 | $3.17 | -0.32% | 8 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $5 → $14 | $13.50 | +3.70% | 18 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $94 → $111 | $84.50 | +31.36% | 4 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $44 | $36.59 | +20.25% | 45 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $46 | $35.47 | +29.69% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $29.03 | +65.35% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 → $8 | $7.69 | +4.03% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $9 | $9.60 | n/a | 19 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 → $12 | $25.24 | n/a | 39 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $4.26 | $6.77 | n/a | 64 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $18 | $4.13 | n/a | 9 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $12 | $1.50 | n/a | 12 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $26 → $17 | $0.67 | n/a | 29 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $0.0082 | n/a | 7 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $3 | $0.6483 | n/a | 5 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $175 | $0.000001 | n/a | 7 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $24.29 | n/a | 1 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2 | $1.03 | n/a | 10 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.014 | n/a | 1 | Nov 11, 2013 |
AbbVie
Jun 23, 2026
Reiterated: Buy
Price Target: $298
Current: $253.35
Upside: +17.62%
Alkermes
Jun 22, 2026
Reiterated: Buy
Price Target: $43
Current: $55.08
Upside: -21.93%
Axsome Therapeutics
Jun 17, 2026
Reiterated: Buy
Price Target: $258
Current: $241.67
Upside: +6.76%
Jazz Pharmaceuticals
Jun 16, 2026
Reiterated: Buy
Price Target: $301
Current: $230.02
Upside: +30.86%
Amgen
Jun 12, 2026
Reiterated: Buy
Price Target: $427
Current: $358.33
Upside: +19.16%
Teva Pharmaceutical Industries
Jun 10, 2026
Reiterated: Buy
Price Target: $42
Current: $33.21
Upside: +26.47%
Viatris
Jun 4, 2026
Maintained: Hold
Price Target: $12
Current: $16.33
Upside: -26.52%
Supernus Pharmaceuticals
Jun 4, 2026
Maintained: Buy
Price Target: $66
Current: $46.84
Upside: +40.91%
Amneal Pharmaceuticals
Jun 4, 2026
Maintained: Buy
Price Target: $17
Current: $17.23
Upside: -1.33%
Bristol-Myers Squibb Company
Jun 3, 2026
Reiterated: Buy
Price Target: $75
Current: $57.52
Upside: +30.39%
Jun 1, 2026
Reiterated: Buy
Price Target: $88
Current: $87.32
Upside: +0.78%
May 29, 2026
Reiterated: Buy
Price Target: $225
Current: $216.03
Upside: +4.15%
May 22, 2026
Reiterated: Buy
Price Target: $54 → $59
Current: $41.83
Upside: +41.05%
May 15, 2026
Reiterated: Buy
Price Target: $18
Current: $11.02
Upside: +63.34%
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $4.39
Upside: +82.23%
May 11, 2026
Maintained: Hold
Price Target: $25 → $21
Current: $21.78
Upside: -3.58%
May 8, 2026
Reiterated: Buy
Price Target: $49 → $48
Current: $44.95
Upside: +6.79%
May 6, 2026
Reiterated: Buy
Price Target: $179 → $207
Current: $168.52
Upside: +22.83%
May 1, 2026
Downgraded: Hold
Price Target: $9 → $3.16
Current: $3.17
Upside: -0.32%
Apr 28, 2026
Upgraded: Hold
Price Target: $5 → $14
Current: $13.50
Upside: +3.70%
Apr 23, 2026
Maintained: Buy
Price Target: $94 → $111
Current: $84.50
Upside: +31.36%
Apr 23, 2026
Maintained: Hold
Price Target: $44
Current: $36.59
Upside: +20.25%
Apr 22, 2026
Reiterated: Buy
Price Target: $48 → $46
Current: $35.47
Upside: +29.69%
Apr 20, 2026
Reiterated: Buy
Price Target: $48
Current: $29.03
Upside: +65.35%
Nov 7, 2025
Maintained: Hold
Price Target: $4 → $8
Current: $7.69
Upside: +4.03%
Mar 21, 2025
Downgraded: Hold
Price Target: $15 → $9
Current: $9.60
Upside: n/a
Nov 7, 2024
Reiterated: Hold
Price Target: $11 → $12
Current: $25.24
Upside: n/a
Oct 31, 2024
Reiterated: Sell
Price Target: $4.26
Current: $6.77
Upside: n/a
May 22, 2024
Reiterated: Buy
Price Target: $21 → $18
Current: $4.13
Upside: n/a
May 14, 2024
Reiterated: Hold
Price Target: $1 → $12
Current: $1.50
Upside: n/a
Aug 9, 2023
Downgraded: Sell
Price Target: $26 → $17
Current: $0.67
Upside: n/a
May 25, 2022
Maintained: Buy
Price Target: $2
Current: $0.0082
Upside: n/a
Nov 10, 2021
Reiterated: Buy
Price Target: $20 → $3
Current: $0.6483
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $175
Current: $0.000001
Upside: n/a
Jan 23, 2019
Upgraded: Hold
Price Target: n/a
Current: $24.29
Upside: n/a
Oct 12, 2017
Reiterated: Hold
Price Target: $3 → $2
Current: $1.03
Upside: n/a
Nov 11, 2013
Initiated Coverage: Buy
Price Target: $6
Current: $0.014
Upside: n/a